Victory Pharma

Acquires, develops and markets prescription pharmaceutical products to treat pain and related conditions

Victory Pharma was a high growth specialty pharmaceutical company in the US with a focus in pain and pain-related conditions. Essex Woodlands identified the pain segment within the specialty pharmaceutical market as an attractive one for investment, and made a growth investment into the company in 2009 to fund the continued expansion of Victory’s lead pain product, NAPRELAN, a once-a-day controlled-release formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID). Shionogi acquired Victory Pharma for $118 million in 2011.